Share This Page
Drug Price Trends for GNP ITCH RELIEF
✉ Email this page to a colleague

Average Pharmacy Cost for GNP ITCH RELIEF
Drug Name | NDC | Price/Unit ($) | Unit | Date |
---|---|---|---|---|
GNP ITCH RELIEF 2%-0.1% SPRAY | 46122-0572-46 | 0.04410 | ML | 2025-01-22 |
GNP ITCH RELIEF 2%-0.1% SPRAY | 46122-0572-46 | 0.04473 | ML | 2024-12-18 |
GNP ITCH RELIEF 2%-0.1% SPRAY | 46122-0572-46 | 0.04454 | ML | 2024-11-20 |
GNP ITCH RELIEF 2%-0.1% SPRAY | 46122-0572-46 | 0.04604 | ML | 2024-10-23 |
GNP ITCH RELIEF 2%-0.1% SPRAY | 46122-0572-46 | 0.04258 | ML | 2024-09-18 |
GNP ITCH RELIEF 2%-0.1% SPRAY | 46122-0572-46 | 0.04087 | ML | 2024-08-21 |
>Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Global Pruritus Therapeutics Market: Analysis and Projections for GNP ITCH RELIEF
Introduction to Pruritus Therapeutics
Pruritus, or itchiness, is a common symptom associated with various dermatological and systemic conditions. The global pruritus therapeutics market has been growing steadily, driven by the increasing prevalence of skin disorders and chronic diseases.
Market Size and Growth Projections
The global pruritus therapeutics market was estimated at USD 8.39 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 4.0% from 2023 to 2030, reaching USD 11.38 billion by 2030[1][4].
Key Drivers of Market Growth
Several factors are driving the growth of the pruritus therapeutics market:
- Growing Prevalence of Associated Conditions: Conditions such as atopic dermatitis, urticaria, and psoriasis are becoming more prevalent, increasing the demand for pruritus treatments[1][4].
- Advancements in Research: Ongoing research efforts are leading to the development of novel therapies and formulations for effective itch relief[4].
- Expanding Geriatric Population: The aging demographic is more prone to various skin ailments, necessitating the use of pruritus medications[4].
- Technological Innovations: Innovations in drug delivery systems enhance the efficacy and convenience of pruritus treatments[4].
Product Outlook
The pruritus therapeutics market is categorized into several product segments:
- Corticosteroids: Dominated the market with a revenue share of 24.07% in 2022 due to their wide range of uses in reducing inflammation and allergic responses[1].
- Calcineurin Inhibitors: Expected to grow at a CAGR of 4.9% during the forecast period due to their strong pipeline and high response rate[1].
- Antihistamines, Local Anesthetics, Counterirritants, and Immunosuppressants: Other significant segments contributing to the market growth[1].
Regional Outlook
- North America: Dominated the market with a revenue share of 39.9% in 2022, driven by the introduction of new products, favorable government initiatives, and the growing prevalence of target diseases[1].
- Europe and Asia Pacific: Also significant regions with growing demand due to increasing prevalence of skin disorders and improving healthcare infrastructure[1].
GNP ITCH RELIEF XS SPRAY
GNP ITCH RELIEF XS SPRAY is a topical treatment available in the market:
- Product Details: This spray is designed for quick and localized relief from itchiness. It is available at a relatively affordable price of $7.19 per 2 oz bottle[2][5].
- Market Position: While specific market share data for GNP ITCH RELIEF XS SPRAY is not available, it falls under the broader category of topical treatments, which are trending due to their ease of application and localized action[4].
Price Projections and Market Trends
Given the overall market trends:
- Topical Treatments: The demand for topical formulations like creams, ointments, and sprays is increasing due to their ease of use and localized action. This trend is expected to continue, benefiting products like GNP ITCH RELIEF XS SPRAY[4].
- Consumer Preferences: There is a growing preference for natural and herbal remedies, which could influence the pricing and demand for products that incorporate such ingredients. However, GNP ITCH RELIEF XS SPRAY's pricing is likely to remain competitive due to its affordability[4].
Competitive Landscape
The global pruritus therapeutics market is highly competitive with various players engaged in extensive R&D to develop novel therapeutics. Key players include Cara Therapeutics, Ulorac, UCB Pharma, Sanofi Aventis, Pfizer, and Actavis Plc. These companies are involved in strategies such as license agreements, collaborations, R&D investments, mergers and acquisitions, and partnerships to increase market penetration[1].
Innovations and Future Outlook
- Itch-Specific Therapies: There is a growing focus on developing therapies specifically targeting itch receptors and pathways to provide targeted relief for pruritus symptoms. This could lead to more advanced and effective treatments in the future[4].
- Digital Health Solutions: The integration of digital health technologies, such as telemedicine and mobile health apps, is expected to enhance patient outcomes and remote monitoring of pruritus, potentially impacting the market dynamics[4].
Key Takeaways
- The global pruritus therapeutics market is expected to grow at a CAGR of 4.0% from 2023 to 2030.
- Corticosteroids dominate the market, but calcineurin inhibitors are expected to grow significantly.
- Topical treatments, including sprays like GNP ITCH RELIEF XS SPRAY, are in high demand due to their ease of application.
- The market is driven by the growing prevalence of skin disorders and advancements in research.
- North America is the largest market segment, driven by new product introductions and favorable government initiatives.
Frequently Asked Questions (FAQs)
1. What is the current size of the global pruritus therapeutics market?
- The global pruritus therapeutics market was estimated at USD 8.39 billion in 2022[1].
2. What is the expected growth rate of the pruritus therapeutics market?
- The market is anticipated to grow at a CAGR of 4.0% from 2023 to 2030[1].
3. Which product segment dominates the pruritus therapeutics market?
- Corticosteroids dominate the market with a revenue share of 24.07% in 2022[1].
4. What are the key drivers of the pruritus therapeutics market growth?
- Growing prevalence of associated conditions, advancements in research, expanding geriatric population, and technological innovations are key drivers[1][4].
5. How does GNP ITCH RELIEF XS SPRAY fit into the market trends?
- GNP ITCH RELIEF XS SPRAY benefits from the trend towards topical treatments due to their ease of application and localized action[4].
Cited Sources:
- Grand View Research: "Pruritus Therapeutics Market Size And Share Report, 2030"
- Laketown Pharmacy: "GNP ITCH RELIEF XS SPRAY 2 OZ"
- Future Market Insights: "USA Compounding Pharmacies Market Growth & Trends 2034"
- Marketresearch.biz: "Pruritus Drugs Market Predicted to Garner USD 12.5 Bn By 2033, At CAGR 4.4% | Exclusive Report by Marketresearch.biz"
- Keaveny Drug: "GNP ITCH RELIEF XS SPRAY 2 OZ"
More… ↓